Samir MD - Novartis Global Relations
| N1VS34 Stock | BRL 67.05 2.21 3.41% |
Insider
Samir MD is Global Relations of Novartis AG
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Amy Miles | Amgen Inc | 52 | |
| Linda Louie | Amgen Inc | 47 | |
| Mike Zahigian | Amgen Inc | N/A | |
| David MD | Amgen Inc | 60 | |
| Joo Almeida | Dimed SA Distribuidora | N/A | |
| David Denton | Pfizer Inc | 58 | |
| DVM DVM | Pfizer Inc | 60 | |
| Eduardo Selva | Dimed SA Distribuidora | N/A | |
| Nancy Grygiel | Amgen Inc | 55 | |
| Sergio Rigon | Dimed SA Distribuidora | N/A | |
| Mikael MD | Pfizer Inc | 65 | |
| Christopher CFA | Pfizer Inc | N/A | |
| Antnio Napp | Dimed SA Distribuidora | N/A | |
| Jennifer Damico | Pfizer Inc | 55 | |
| Julio Neto | Dimed SA Distribuidora | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor, Chief Sandoz | ||
| Steffen Lang, Pres Operations | ||
| MarieFrance Tschudin, Pres Officer | ||
| Paul Penepent, Head Accounting | ||
| Samir MD, Global Relations | ||
| Robert PharmD, Chief Officer | ||
| Klaus Moosmayer, Risk Ethics | ||
| Karen Hale, Chief Officer | ||
| Vasant Narasimhan, Chief Officer | ||
| Harry Kirsch, Chief Officer |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.1 T | |||
| Shares Outstanding | 2.12 B | |||
| Price To Earning | 15.16 X | |||
| Price To Book | 0.33 X | |||
| Price To Sales | 19.86 X | |||
| Revenue | 52.88 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Novartis Stock
Novartis financial ratios help investors to determine whether Novartis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.